DK2742045T3 - Antibakteriel cyclopenta[c]pyrrolsubstituerede 3,4-dihydro-1h-[1,8]naphthyridinoner - Google Patents
Antibakteriel cyclopenta[c]pyrrolsubstituerede 3,4-dihydro-1h-[1,8]naphthyridinoner Download PDFInfo
- Publication number
- DK2742045T3 DK2742045T3 DK12746093.9T DK12746093T DK2742045T3 DK 2742045 T3 DK2742045 T3 DK 2742045T3 DK 12746093 T DK12746093 T DK 12746093T DK 2742045 T3 DK2742045 T3 DK 2742045T3
- Authority
- DK
- Denmark
- Prior art keywords
- mmol
- formula
- hydrogen
- alkyl
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (16)
1. Forbindelse med formel (I)
hvor A er
:^-bindingen er en enkeltbinding eller en dobbeltbinding, X er carbon eller nitrogen, og når X er nitrogen, så er bindingen en enkeltbinding; Zi er CH eller N; R1 er hydrogen, Ci-4alkyl eller halogen; R2 er hydrogen, Ci-4alkyl eller halogen; R3 er hydrogen, Ci-6alkyl, hydroxy eller halogen; R4 er hydrogen; halogen; Ci-6alkyl; C2-6alkenyl; C2-6alkynyl; Ci-6alkyloxy; Ci-4alkyloxycarbonyl; aminocarbonyl; mono- eller di (Ci-4alkyl)-aminocarbonyl; aryl; aryloxy; arylcarbonyl; arylsulfonyl; heteroaryl; Ci-6alkyl substitueret med cyano; Ci-6alkyl substitueret med aryl eller aryloxy; eller Ci-6alkyl substitueret med heteroaryl; aryl er phenyl; phenyl substitueret med en, to eller tre substituenter, der hver for sig er valgt blandt halogen, hydroxy, Ci-4alkyl, Ci-4alkyloxy, polyhalogenCi-4alkyl, polyhalogenCi-4alkyloxy, cyano, nitro og amino; heteroaryl er furanyl, thiophenyl, pyrrolyl, pyrazolyl, imidazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, isothiazolyl, thiadiazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, benzo[1,3]dioxolyl, benzofuranyl, benzothiazolyl, indolyl, 2,3-dihydro-lH-indolyl, tetrahydrothiophenyl eller quinolinyl, hvor hver heteroaryl kan være substitueret med en eller to substituenter, der hver for sig er valgt blandt halogen, cyano, Ci-4alkyl, Ci-4alkyloxy, Ci-4alkylcarbonyl eller phenyl; eller et farmaceutisk acceptabelt syreadditionssalt deraf.
2. Forbindelse ifølge krav 1, hvor: Zi er CH; R1 er hydrogen eller Ci-4alkyl; R2 er hydrogen eller Ci-4alkyl.
3. Forbindelse ifølge krav 1 eller krav 2, hvor A er
T^-bindingen er en enkeltbinding eller en dobbeltbinding, X er carbon eller nitrogen, og når X er nitrogen, så er Tilbindingen en enkeltbinding; R1 er hydrogen; R2 er hydrogen; R3 er hydrogen, hydroxy eller halogen; R4 er hydrogen; halogen; Ci-6alkyl; Ci-6alkyloxy; Ci- 4alkyloxycarbonyl; aminocarbonyl; mono- eller di(Ci-4alkyl)-aminocarbonyl; aryl; aryloxy; arylsulfonyl; heteroaryl; Ci-6alkyl substitueret med cyano; Ci-6alkyl substitueret med aryl eller aryloxy; eller Ci-6alkyl substitueret med heteroaryl; aryl er phenyl; phenyl substitueret med én substituent valgt blandt halogen, Ci-4alkyl, Ci-4alkyloxy og cyano; heteroaryl er furanyl, thiophenyl, pyrazolyl, isoxazolyl, thiazolyl, triazolyl, tetrazolyl, thiadiazolyl, pyridinyl eller pyrimidinyl, hvor hver heteroaryl kan være substitueret med én substituent valgt blandt halogen, cyano, Ci-4alkyl, Ci-4alkyloxy eller Ci-4alkylcarbonyl; eller et farmaceutisk acceptabelt syreadditionssalt deraf.
4. Forbindelse ifølge et hvilket som helst af kravene 1 til 3, hvor R1 er hydrogen, og R2 er hydrogen.
5. Forbindelse ifølge et hvilket som helst af kravene 1 til 4, hvor R3 er hydrogen.
6. Forbindelse ifølge et hvilket som helst af kravene 1 til 5, hvor R4 er aryl.
Ί. Forbindelse ifølge et hvilket som helst af kravene 1 til 5, hvor R4 er heteroaryl.
8. Forbindelse ifølge et hvilket som helst af kravene 1 til 5, hvor R4 er Ci-6alkyl substitueret med aryl.
9. Forbindelse ifølge et hvilket som helst af kravene 1 til 8, hvor X er nitrogen, og 7T7TT:-bindingen er en enkeltbinding.
10. Forbindelse ifølge et hvilket som helst af kravene 1 til 9, hvor A er
11. Forbindelse ifølge krav 1 valgt blandt følgende:
eller et farmaceutisk acceptabelt salt deraf.
12. Farmaceutisk sammensætning, der omfatter et farmaceutisk acceptabelt bæremateriale og en terapeutisk aktiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 11.
13. Fremgangsmåde til fremstilling af en farmaceutisk sammensætning ifølge krav 12, hvor en terapeutisk aktiv mængde af en forbindelse ifølge et hvilket som helst af kravene 1 til 11 blandes grundigt med et farmaceutisk acceptabelt bæremateriale.
14. Forbindelse med formel (I) ifølge et hvilket som helst af kravene 1 til 11 til anvendelse som en medicin.
15. Forbindelse med formel (I) ifølge et hvilket som helst af kravene 1 til 11 til anvendelse til behandling af bakterieinfektioner.
16. Forbindelse ifølge krav 15, hvor bakterieinfektionen er forårsaget af en bakterie, der udtrykket et Fabl-enzym.
17. Fremgangsmåde til fremstilling af forbindelser med formel (I) ifølge krav 1: (i) ved hjælp af reaktion af et mellemprodukt med formel (II) med et mellemprodukt med formel (III),
(ii) for forbindelser med formel (I), hvori A er -C(R2) =C (R1)-, ved hjælp af reaktion af et mellemprodukt med formel (V) med et mellemprodukt med formel (VI),
hvor Xai er en egnet fraspaltelig enhed, og de andre elementer er som defineret i krav 1; eller; om ønsket; en forbindelse med formel (I) omdannes til et farmaceutisk acceptabelt syreadditionssalt, eller omvendt et syreadditionssalt af en forbindelse med formel (I) omdannes
til en fri baseform med alkali.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11177119 | 2011-08-10 | ||
| PCT/EP2012/065733 WO2013021054A1 (en) | 2011-08-10 | 2012-08-10 | Antibacterial cyclopenta[c]pyrrole substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2742045T3 true DK2742045T3 (da) | 2019-04-23 |
Family
ID=46650549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK12746093.9T DK2742045T3 (da) | 2011-08-10 | 2012-08-10 | Antibakteriel cyclopenta[c]pyrrolsubstituerede 3,4-dihydro-1h-[1,8]naphthyridinoner |
Country Status (24)
| Country | Link |
|---|---|
| US (7) | US8906923B2 (da) |
| EP (1) | EP2742045B1 (da) |
| JP (2) | JP5921687B2 (da) |
| KR (1) | KR101996862B1 (da) |
| CN (2) | CN103874698B (da) |
| AR (1) | AR087508A1 (da) |
| AU (1) | AU2012293621B2 (da) |
| BR (1) | BR112014003063B1 (da) |
| CA (1) | CA2842518C (da) |
| CL (1) | CL2014000289A1 (da) |
| DK (1) | DK2742045T3 (da) |
| EA (1) | EA201490438A1 (da) |
| ES (1) | ES2721658T3 (da) |
| HK (2) | HK1199243A1 (da) |
| HU (1) | HUE042978T2 (da) |
| IL (1) | IL230549A (da) |
| JO (1) | JO3611B1 (da) |
| MX (1) | MX348128B (da) |
| PE (1) | PE20141410A1 (da) |
| TR (1) | TR201905537T4 (da) |
| TW (1) | TWI568731B (da) |
| UA (1) | UA111210C2 (da) |
| UY (1) | UY34253A (da) |
| WO (1) | WO2013021054A1 (da) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2842531C (en) | 2011-08-10 | 2019-07-16 | Janssen R&D Ireland | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| JO3611B1 (ar) | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
| CA2879623C (en) * | 2012-08-10 | 2021-11-02 | Janssen Sciences Ireland Uc | Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi |
| EP3461827B1 (en) | 2013-09-26 | 2022-02-23 | Cadent Therapeutics, Inc. | Selective octahydro-cyclopenta[c]pyrrole negative modulators of nr2b |
| JO3579B1 (ar) | 2014-09-26 | 2020-07-05 | Luc Therapeutics Inc | مُعدِلات تفاغرية سالبة لمستقبل nr2b من المركب n-ألكيل أريل-5-أوكسي أريل-ثامن هيدرو-خماسي الحلقة [c] بيرول |
| KR102007135B1 (ko) | 2017-03-20 | 2019-08-02 | 포르마 세라퓨틱스 인크. | 피루베이트 키나제 (pkr) 활성화제로서의 피롤로피롤 조성물 |
| US11691967B2 (en) | 2018-03-12 | 2023-07-04 | The Board Of Trustees Of The University Of Illinois | Antibiotics effective for gram-negative pathogens |
| JP7450610B2 (ja) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | ピルビン酸キナーゼｒの活性化 |
| CN113166060B (zh) | 2018-09-19 | 2024-01-09 | 诺沃挪第克健康护理股份公司 | 用丙酮酸激酶激活化合物治疗镰状细胞病 |
| AU2019380568B2 (en) | 2018-11-12 | 2024-08-15 | Debiopharm International S.A. | Antibiotic compounds, methods of manufacturing the same, pharmaceutical compositions containing the same and uses thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4215123A (en) * | 1979-05-07 | 1980-07-29 | American Home Products Corporation | Antisecretory 4-oxy-3-carboxy or cyano-1,2-dihydro-2-oxo-1,8-naphthyridine derivatives |
| AR025976A1 (es) | 1999-10-08 | 2002-12-26 | Affinium Pharm Inc | Inhibidores de fab i. |
| AU7866300A (en) | 1999-10-08 | 2001-04-23 | Smithkline Beecham Corporation | Fab i inhibitors |
| EP1225895B1 (en) | 1999-10-08 | 2005-05-04 | Affinium Pharmaceuticals, Inc. | Fab i inhibitors |
| ES2320984T3 (es) * | 2001-04-06 | 2009-06-01 | Affinium Pharmaceuticals, Inc. | Inhibidores de fab i. |
| KR101299399B1 (ko) * | 2004-06-04 | 2013-08-22 | 아피늄 파마슈티컬스, 인크. | 치료제, 및 그의 제조 및 사용 방법 |
| US7732612B2 (en) | 2004-09-09 | 2010-06-08 | Janssen Pharmaceutica, N.V. | 7-amino alkylidenyl-heterocyclic quinolones and naphthyridones |
| US7973060B2 (en) | 2005-10-13 | 2011-07-05 | Crystalgenomics, Inc. | Fab I inhibitor and process for preparing same |
| CA2658506C (en) | 2006-07-20 | 2016-01-26 | Affinium Pharmaceuticals, Inc. | Acrylamide derivatives as fab 1 inhibitors |
| US8263613B2 (en) * | 2007-02-16 | 2012-09-11 | Affinium Pharmaceuticals, Inc. | Salts, prodrugs and polymorphs of fab I inhibitors |
| PL2501693T3 (pl) * | 2009-11-18 | 2015-03-31 | Fab Pharma Sas | Azaheterocykliczne akryloamidy i ich zastosowanie jako środków bakteriobójczych |
| JP2014524409A (ja) | 2011-07-29 | 2014-09-22 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | Ｈｉｖの治療のための組成物および方法 |
| US8766017B2 (en) | 2011-07-29 | 2014-07-01 | Eastman Chemical Company | Integrated process for the preparation of 1,4-cyclohexanedimethanol from terephthalic acid |
| CA2842526C (en) | 2011-08-10 | 2019-07-23 | Janssen R&D Ireland | Antibacterial homopiperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| CA2842531C (en) | 2011-08-10 | 2019-07-16 | Janssen R&D Ireland | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones |
| JO3611B1 (ar) * | 2011-08-10 | 2020-08-27 | Janssen Sciences Ireland Uc | سايكلو بنتا (سي (بيرول 4,3 ثاني هيدرو 1 hمستبدله [8,1] نافثيريدينونات مضادة للجراثيم |
-
2012
- 2012-08-07 JO JOP/2012/0223A patent/JO3611B1/ar active
- 2012-08-10 CA CA2842518A patent/CA2842518C/en active Active
- 2012-08-10 EA EA201490438A patent/EA201490438A1/ru unknown
- 2012-08-10 TW TW101128885A patent/TWI568731B/zh active
- 2012-08-10 WO PCT/EP2012/065733 patent/WO2013021054A1/en active Application Filing
- 2012-08-10 MX MX2014001600A patent/MX348128B/es active IP Right Grant
- 2012-08-10 PE PE2014000186A patent/PE20141410A1/es active IP Right Grant
- 2012-08-10 AR ARP120102929A patent/AR087508A1/es active IP Right Grant
- 2012-08-10 AU AU2012293621A patent/AU2012293621B2/en active Active
- 2012-08-10 EP EP12746093.9A patent/EP2742045B1/en active Active
- 2012-08-10 ES ES12746093T patent/ES2721658T3/es active Active
- 2012-08-10 TR TR2019/05537T patent/TR201905537T4/tr unknown
- 2012-08-10 CN CN201280038643.4A patent/CN103874698B/zh active Active
- 2012-08-10 BR BR112014003063-4A patent/BR112014003063B1/pt active IP Right Grant
- 2012-08-10 DK DK12746093.9T patent/DK2742045T3/da active
- 2012-08-10 US US14/237,862 patent/US8906923B2/en active Active
- 2012-08-10 HU HUE12746093A patent/HUE042978T2/hu unknown
- 2012-08-10 CN CN201511000870.XA patent/CN105461684B/zh active Active
- 2012-08-10 JP JP2014524410A patent/JP5921687B2/ja active Active
- 2012-08-10 UY UY0001034253A patent/UY34253A/es active IP Right Grant
- 2012-08-10 KR KR1020147005329A patent/KR101996862B1/ko active IP Right Grant
- 2012-10-08 UA UAA201400628A patent/UA111210C2/uk unknown
-
2014
- 2014-01-20 IL IL230549A patent/IL230549A/en active IP Right Grant
- 2014-02-05 CL CL2014000289A patent/CL2014000289A1/es unknown
- 2014-11-24 US US14/552,108 patent/US9290493B2/en active Active
- 2014-12-18 HK HK14112687.7A patent/HK1199243A1/zh unknown
-
2016
- 2016-03-16 US US15/071,612 patent/US9617262B2/en active Active
- 2016-04-12 JP JP2016079689A patent/JP2016190843A/ja not_active Withdrawn
- 2016-10-03 HK HK16111498.6A patent/HK1223352A1/zh unknown
-
2017
- 2017-03-09 US US15/454,703 patent/US9884864B2/en active Active
- 2017-12-18 US US15/845,854 patent/US10155759B2/en active Active
-
2018
- 2018-11-16 US US16/194,052 patent/US10501463B2/en active Active
-
2019
- 2019-02-26 US US16/286,383 patent/US10526331B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2742045T3 (da) | Antibakteriel cyclopenta[c]pyrrolsubstituerede 3,4-dihydro-1h-[1,8]naphthyridinoner | |
| AU2012293619B2 (en) | Antibacterial piperidinyl substituted 3,4-dihydro-1h-[1,8]naphthyridinones | |
| AU2012293618B2 (en) | Antibacterial homopiperidinyl substituted 3,4 dihydro 1H (1,8)naphthyridinones | |
| CA2879623A1 (en) | Fused bicyclic azole heterocycle as inhibitors of the enzyme fabi | |
| EA043636B1 (ru) | АНТИБАКТЕРИАЛЬНЫЕ 3,4-ДИГИДРО-1Н-[1,8]НАФТИРИДИНОНЫ, ЗАМЕЩЕННЫЕ ЦИКЛОПЕНТА[с]ПИРРОЛОМ |